Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 3/2013

01-03-2013 | Original Article

Analysis of Genetic Damage and Gene Polymorphism in Hepatocellular Carcinoma (HCC) Patients in a South Indian Population

Authors: Subramaniam Mohana Devi, Vellingiri Balachandar, Meyyazhagan Arun, Shanmugam Suresh Kumar, Balasubramanian Balamurali Krishnan, Keshavarao Sasikala

Published in: Digestive Diseases and Sciences | Issue 3/2013

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in many regions of Asia and the etiology of human HCC is clearly multi-factorial. The development of effective markers for the detection of HCC could have an impact on cancer mortality and significant health implications worldwide. The subjects presented here were recruited based on the serum alpha-fetoprotein level, which is an effective marker for HCC. Further, the chromosomal alterations were elucidated using trypsin G-banding. HCCs with p53 mutations have high malignant potential and are used as an indicator for the biological behavior of recurrent HCCs. The functional polymorphism in the XRCC1 gene, which participates in the base-excision repair of oxidative DNA damage, was associated with increased risk of early onset HCC. Thus, in this investigation, the p53 and XRCC1 gene polymorphisms using the standard protocols were also assessed to find out whether these genes may be associated with HCC susceptibility.

Methods

Blood samples from HCC patients (n = 93) were collected from oncology clinics in South India. Control subjects (n = 93) who had no history of tumors were selected and they were matched to cases on sex, age, and race. Peripheral blood was analyzed for chromosomal aberrations (CAs) and micronuclei (MN) formation. p53 and XRCC1 genotypes were detected using a PCR–RFLP technique.

Results

Specific biomarkers on cytogenetic endpoints might help in diagnosis and treatment measures. The frequencies of genotypes between groups were calculated by χ2 test. A statistically significant (p < 0.05) increase in CA was observed in HCC patients compared to their controls as confirmed by ANOVA and MN shows insignificant results. The study on p53 Arg72Pro and XRCC1 Arg399Gln polymorphism in HCC patients demonstrated differences in allele frequencies compared to their controls.

Conclusions

The present study indicates that chromosomal alterations and the genetic variations of p53 and XRCC1 may contribute to inter-individual susceptibility to HCC. A very limited role of genetic polymorphism was investigated in modulating the HCC risk, but the combined effect of these variants may interact to increase the risk of HCC in the South Indian population.
Literature
1.
2.
Motola Kuba D, Zamora Valdes D, Uribe M, et al. Hepatocellular carcinoma. An overview. Ann Hepatol. 2006;5:16–24.PubMed
3.
Villa VD, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist. 2007;12:132–1331.CrossRef
4.
Bu X, Jia F, Wang W, et al. Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells. Bio Med Central Cancer. 2007;7:208–215.
5.
Chakraborty T, Bhuniya D, Chatterjee M, et al. Acanthus ilicifolius plant extract prevents DNA alterations in a transplantable Ehrlich ascites carcinoma-bearing murine model. World J Gastroenterol. 2007;13:6538–6548.PubMedCrossRef
6.
7.
Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008;121:525–531.PubMedCrossRef
8.
Cha C, Fong Y, Jarnagin WR, et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197:753–758.PubMedCrossRef
9.
Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–66.PubMedCrossRef
10.
Zheng SS, Xu X, Liang TB, et al. Liver transplantation for hepatocellular carcinoma: prognostic analysis of 89 cases. Zhonghua Wai Ke Za Zhi. 2005;43:450–454.PubMed
11.
Xu X, Ke QH, Shao Z-X, et al. The value of serum a-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci. 2009;54:385–388.PubMedCrossRef
12.
Albertini RJ, Anderson D, Douglas GR, et al. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat Res. 2000;463:111–172.PubMedCrossRef
13.
Norppa H. Cytogenetic biomarkers. In: Mechanistic Considerations in the Molecular Epidemiology of Cancer. Lyon: IARC Science Publication; 2004:157.
14.
Hagmar LS, Bonassi U, Strömberg A, et al. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res. 1998;58:4117–4121.PubMed
15.
Bonassi S, Hagmar L, Strömberg U, et al. European Study Group on cytogenetic biomarkers and health. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res. 2000;60:1619–1625.PubMed
16.
Bonassi S, Znaor A, Ceppi C, et al. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis. 2007;28:331–338.
17.
Grisham JW. Molecular genetic alterations in primary hepatocellular neoplasms: hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma. In: Coleman WB, Tsongalis GJ, eds. The Molecular Basis of Human Cancer. Totowa: Humana Press Inc.; 2002:269–346.
18.
Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–346.PubMedCrossRef
19.
Midorikawa Y, Yamamoto S, Ishikawa S, et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene. 2006;25:5581–5590.PubMedCrossRef
20.
Balachandar V, Mohana Devi S, Lakshman Kumar B, et al. Cytogenetic analysis of benign prostate hyperplasia (BPH) and prostate cancer (PC) patients from Tamil Nadu, South India. Sci Res Essay (Academic Journal Publication). 2008;3:212–214.
21.
Mohana Devi S, Balachandar V, Vel Murugan P, et al. Identification of chromosomal aberrations by using trypsin G- banding in hepatocellular carcinoma patients (HCC) in Tamilnadu, India. Trop Life Sci Res. 2010;21:33–49.
22.
Wong N, Lai P, Pang E, et al. Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin Cancer Res. 2000;6:4000–4009.PubMed
23.
Lu XG, Magrane C, Yin DN, et al. Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol Cell Biol. 2001;21:6017–6030.PubMedCrossRef
24.
Sheen IS, Jeng KS, Wu JY, et al. Is p53 gene mutation an indicator of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol. 2003;9:1202–1207.PubMed
25.
Staib F, Hussain SP, Hofseth LJ, et al. TP53 and liver carcinogenesis. Hum Mutat. 2003;21:201–216.PubMedCrossRef
26.
27.
Duell EJ, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis Lond. 2000;21:965–971.CrossRef
28.
Liu F, Li B, Wei Y, Yan L, et al. XRCC1 genetic polymorphism Arg399Gln and hepatocellular carcinoma risk: a meta-analysis. Liver Int. 2011;6:802–809.CrossRef
29.
Yu J, Zhang HY, Ma ZZ, et al. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res. 2003;13:319–333.PubMedCrossRef
30.
Whitehouse CJ, Taylor RM, Thistlethwaite A. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 2001;104:107–117.PubMedCrossRef
31.
Moorhead PS, Novell WJ, Mellman DM, et al. Chromosome preparations of leukocytes cultured from peripheral blood. Exp Cell Res. 1960;20:613–616.PubMedCrossRef
32.
Martin Bland J, Douglas G. Altman Statistics Notes: the odds ratio. BMJ. 2000;320:1468.CrossRef
33.
34.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–1491.PubMedCrossRef
35.
36.
Jia HL, Ye QH, Qin LX. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007;13:1133.PubMedCrossRef
37.
38.
Um SH, Mulhall C, Alisa A. a-Fetoprotein impairs APC function and induces their apoptosis. J Immunol. 2004;173:1772–1778.PubMed
39.
Tilghman SM. The structure and regulation of the a-fetoprotein and albumin genes. Oxf Surv Eukaryot Genes. 1985;2:160–206.PubMed
40.
Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6:241–247.PubMed
41.
Otsuru A, Nagataki S, Koji T, et al. Analysis of alpha-fetoprotein gene expression in hepatocellular carcinoma and liver cirrhosis by in situ hybridization. Cancer. 1988;62:1105–1112.PubMedCrossRef
42.
43.
Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitomes, and conformational variants. Exp Biol Med. 2001;226:377–408.
44.
45.
Piao Z, Park C, Park JH, Kim H. Allelotype analysis of hepatocellular carcinoma. Int J Cancer. 1998;75:29–33.PubMedCrossRef
46.
Guan XY, Fang Y, Sham JS, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2000;29:110–116.PubMedCrossRef
47.
Chang J, Kim NG, Piao Z, et al. Assessment of chromosomal losses and gains in hepatocellular carcinoma. Cancer Lett. 2002;182:193–202.PubMedCrossRef
48.
Jou YS, Lee CS, Chang YH. Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. Cancer Res. 2004;64:3030–3036.PubMedCrossRef
49.
50.
Niketeghad F, Decker HJ, Caselmann WH, et al. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer. 2001;85:697–704.PubMedCrossRef
51.
Yeh SH, Chen PJ, Shau WY, et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology. 2001;121:699–709.PubMedCrossRef
52.
Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120:1763–1773.PubMedCrossRef
53.
Patil MA, Gutgemann I, Zhang J, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and JAB1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis. 2005;26:2050–2057.
54.
Sheu JC. Molecular mechanism of hepatocarcinogenesis. J Gastroenterol Hepatol. 1997;12:S309–S313.PubMedCrossRef
55.
Norppa H, Luomahaara S, Heikanen H, et al. Micronucleus assay in lymphocytes as a tool to biomonitor human exposure to aneuploidogens and clastogens. Environ Health Perspect. 1993;101:139–143.PubMed
56.
Fenech M. Cytokinesis-block micronucleus assay. Nature Protocols. 2007;2:1084–1104.
57.
de Almeida TMB, Leitao RC, et al. Carrilhod, Shigueko Sonoharae, Detection of micronuclei formation and nuclear anomalies in regenerative nodules of human cirrhotic livers and relationship to hepatocellular carcinoma. Cancer Genet Cytogenet. 2004;150:16–21.PubMedCrossRef
58.
Bonassi S, Znaor A, Ceppi M, et al. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis. 2007;28:625–631.PubMedCrossRef
59.
Fenech M, Denham J, Francis W, Morely A. Micronuclei in cytokinesis blocked lymphocytes of cancer patients following fractionated partial-body radiotherapy. Int J Radiat Biol. 1990;57:373–383.PubMedCrossRef
60.
Gantenberg HW, Wuttke K, Streffer C, Muller WU. Micronuclei in human lymphocytes irradiated in vitro or in vivo. Radiat Res. 1991;128:276–281.PubMedCrossRef
61.
Livezey KW, Negorev D, Simon D. Increased chromosomal alterations and micronuclei formation in human hepatoma HepG2 cells transfected with the hepatitis B virus HBX gene. Mutat Res. 2002;505:63–74.PubMedCrossRef
62.
Umegaki K, Fenech M. Cytokinesis-block micronucleus assay in WIL2-NS cells: a sensitive system to detect chromosomal damage induced by reactive oxygen species and activated human neutrophils. Mutagenesis. 2000;15:261–269.PubMedCrossRef
63.
Countryman PI, Heddle JA. The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat Res. 1976;41:321–332.PubMedCrossRef
64.
Cliet I, Fournier E, Melcion C, et al. In vivo micronucleus test using mouse hepatocytes. Mutat Res. 1989;216:321–326.PubMedCrossRef
65.
Van Goethem F, Ghahroudi MA, Castelain P, et al. Frequency and DNA content of micronuclei in rat parenchymal liver cells during experimental hepatocarcinogenesis. Carcinogenesis. 1993;14:2397–2406.PubMedCrossRef
66.
Fenech M, Holland N, Chang WP, et al. The Human MicroNucleus Project—an international collaborative study on the use of the micronucleus technique for measuring DNA damage in humans. Mutat Res. 1999;428:271–283.PubMedCrossRef
67.
68.
Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429–431.PubMedCrossRef
69.
Tudek B. Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med. 2007;28:258–275.PubMedCrossRef
70.
Au WW. Heritable susceptibility factors for the development of cancer. J Radiat Res. 2006;47:13–17.CrossRef
71.
Cornetta T, Festa F, Testa A, Cozzi R. DNA damage repair and genetic polymorphisms: assessment of individual sensitivity and repair capacity. Int J Radiat Oncol Biol Phys. 2006;66:537–545.PubMedCrossRef
72.
Vettriselvi V, Vijayalakshmi K, Solomon PF. XRCC1 and XPD gene polymorphisms in a South Indian population. Asian Pac J Cancer. 2007;8:283–286.
73.
Wang G, Zhao Y, Liu X, et al. Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes Cancer. 2001;31:221–227.PubMedCrossRef
74.
Okabe H, Ikai I, Matsuo K, et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology. 2000;31:1073–1079.PubMedCrossRef
Metadata
Title
Analysis of Genetic Damage and Gene Polymorphism in Hepatocellular Carcinoma (HCC) Patients in a South Indian Population
Authors
Subramaniam Mohana Devi
Vellingiri Balachandar
Meyyazhagan Arun
Shanmugam Suresh Kumar
Balasubramanian Balamurali Krishnan
Keshavarao Sasikala
Publication date
01-03-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2409-8

Other articles of this Issue 3/2013

Digestive Diseases and Sciences 3/2013 Go to the issue

Editorial

Covering Digestive Diseases and Sciences: How to Judge a Journal by Its Cover

Original Article

Prospective Markers for Early Diagnosis and Prognosis of Sporadic Pancreatic Ductal Adenocarcinoma

Correspondence

Letter in Response to the Recently Published Review: Hyponatremia in Cirrhosis and End-Stage Liver Disease—Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

Review

Eosinophilic Esophagitis: Current Treatment

Original Article

Percutaneous Endoscopic Gastrostomy in Cancer Patients: Predictors of 30-Day Complications, 30-Day Mortality, and Overall Mortality

Original Article

Lubiprostone Decreases Mouse Colonic Inner Mucus Layer Thickness and Alters Intestinal Microbiota
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits